{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:26:06Z","timestamp":1793287566995,"version":"4.5.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A unique transient leukemia (TL) has been described in newborns with Down syndrome (DS; or trisomy 21 mosaics). This leukemia has a high incidence of spontaneous remission; however, early death and subsequent development of acute megakaryoblastic leukemia (AMKL) have been reported. We prospectively evaluated 48 infants with DS and TL to determine the natural history and biologic characteristics of this disease, identify the clinical characteristics associated with early death or subsequent leukemia, and assess the incidence of subsequent leukemia. Blast cells associated with TL in DS infants exhibited FAB M7 morphology and phenotype. Most infants (74%) had trisomy 21 (or mosaicism) as the only cytogenetic abnormality in the blast cells. Most children were able to spontaneously clear peripheral blasts (89%), normalize blood counts (74%), and maintain a complete remission (64%). Early death occurred in 17% of infants and was significantly correlated with higher white blood cell count at diagnosis (P &lt; .001), increased bilirubin and liver enzymes (P &lt; .005), and a failure to normalize the blood count (P = .001). Recurrence of leukemia occurred in 19% of infants at a mean of 20 months. Development of leukemia was significantly correlated with karyotypic abnormalities in addition to trisomy 21 (P = .037). Ongoing collaborative clinical studies are needed to determine the optimal role of chemotherapy for infants at risk for increased mortality or disease recurrence and to further the knowledge of the unique biologic features of this TL.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2448","type":"journal-article","created":{"date-parts":[[2006,2,10]],"date-time":"2006-02-10T01:44:00Z","timestamp":1139535840000},"page":"4606-4613","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":256,"title":["A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481"],"prefix":"10.1182","volume":"107","author":[{"given":"Gita V.","family":"Massey","sequence":"first","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Zipursky","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron N.","family":"Chang","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Doyle","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Nasim","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaddanapudi","family":"Ravindranath","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Dahl","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard J.","family":"Weinstein","sequence":"additional","affiliation":[{"name":"From Virginia Commonwealth University, Medical College of Virginia, Richmond; Hospital for Sick Children, Toronto, ON, Canada; Children's Oncology Group Statistical Office, Gainesville, FL; Children's Hospital of Michigan, Detroit; Stanford University School of Medicine, CA; and Massachusetts General Hospital for Children, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111806360633500_REF1","doi-asserted-by":"crossref","unstructured":"Zipursky A, Rose T, Skidmore M, et al. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol. 1996;13: 81-87.","DOI":"10.3109\/08880019609033374"},{"key":"2019111806360633500_","unstructured":"Broadbent VA. Malignant disease in the neonate. In: Roberton NRC, ed. Textbook of Neonatology, ed. 2 Edinburgh, United Kingdom: Churchill Livingstone; 1992: 879."},{"key":"2019111806360633500_REF3","doi-asserted-by":"crossref","unstructured":"Robison LL, Nesbit ME, Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children's Cancer Study Group. J Pediatr. 1984;105: 235-242.","DOI":"10.1016\/S0022-3476(84)80119-5"},{"key":"2019111806360633500_REF4","doi-asserted-by":"crossref","unstructured":"Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9: 139-149.","DOI":"10.3109\/08880019209018329"},{"key":"2019111806360633500_REF5","doi-asserted-by":"crossref","unstructured":"Zipursky A, Brown E, Christensen H, et al. Leukemia and\/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol. 1997;21: 97-101.","DOI":"10.1016\/S0146-0005(97)80025-0"},{"key":"2019111806360633500_REF6","doi-asserted-by":"crossref","unstructured":"Schunk GJ, Lehman WL. Mongolism and congenital leukemia. JAMA. 1954;155: 250-251.","DOI":"10.1001\/jama.1954.73690210004006b"},{"key":"2019111806360633500_REF7","doi-asserted-by":"crossref","unstructured":"Weinstein HJ. Congenital leukemia and the neonatal myeloproliferative disorders associated with Down syndrome: a report. Clin Haematol. 1978;7: 147-154.","DOI":"10.1016\/S0308-2261(21)00575-0"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Wong KY, Jones MM, Svrivastava AK, et al. Transient myeloproliferative disorder and acute nonlymphoblastic leukemia in Down syndrome. J Pediatr. 1988;112: 18-22.","DOI":"10.1016\/S0022-3476(88)80112-4"},{"key":"2019111806360633500_","unstructured":"Paolucci G, Rosito P. Neonatal myeloproliferative disorders in Down syndrome and congenital leukemias. Haematologica. 1987;72: 121-125."},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Nakagawa T, Nishida H, Arai T, et al. Hyperviscosity syndrome with transient abnormal myelopoiesis in Down syndrome. J Pediatr. 1988;112: 58-61.","DOI":"10.1016\/S0022-3476(88)80122-7"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Becroft DMO, Zwi LJ. Perinatal visceral fibrosis accompanying the megakaryoblastic leukemoid reaction to Down syndrome. Pediatr Pathol. 1990;10: 397-406.","DOI":"10.3109\/15513819009067127"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Ruchelli ED, Uri A, Dimmick JE, et al. Severe perinatal liver disease and Down syndrome: an apparent relationship. Hum Pathol. 1991;22: 1274-1280.","DOI":"10.1016\/0046-8177(91)90111-2"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Miyauchi J, Ito Y, Kawano, T, et al. Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood. 1992;80: 1521-1527.","DOI":"10.1182\/blood.V80.6.1521.1521"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Foucar K, Friedman K, Llewellyn A, et al. Prenatal diagnosis of transient myeloproliferative disorder via percutaneous umbilical blood sampling. Report of two cases in fetuses affected by Down syndrome. Am J Clin Pathol. 1992;97: 584-590.","DOI":"10.1093\/ajcp\/97.4.584"},{"key":"2019111806360633500_REF15","unstructured":"Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol. 1993;15: 392-399."},{"key":"2019111806360633500_REF16","doi-asserted-by":"crossref","unstructured":"Al-Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2002;24: 9-13.","DOI":"10.1097\/00043426-200201000-00004"},{"key":"2019111806360633500_REF17","doi-asserted-by":"crossref","unstructured":"Issacs H. Fetal and neonatal leukemia. J Pediatr Hematol Oncol. 2003;25: 348-361.","DOI":"10.1097\/00043426-200305000-00002"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Barnett PL, Clark AC, Garson OM. Acute nonlymphocytic after transient myeloproliferative disorder in a patient with Down syndrome. Med Pediatr Oncol. 1990;18: 347-353.","DOI":"10.1002\/mpo.2950180502"},{"key":"2019111806360633500_REF19","doi-asserted-by":"crossref","unstructured":"Doyle JJ, Thorner P, Poon A, et al. Transient leukemia followed by megakaryoblastic leukemia in a child with mosaic Down syndrome. Leuk Lymphoma. 1995;17: 345-350.","DOI":"10.3109\/10428199509056843"},{"key":"2019111806360633500_REF20","doi-asserted-by":"crossref","unstructured":"Alman BA, Pajerski ME, Diaz-Cano S, et al. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol. 1997;6: 98-101.","DOI":"10.1097\/00019606-199704000-00005"},{"key":"2019111806360633500_REF21","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;35: 457-481."},{"key":"2019111806360633500_REF22","doi-asserted-by":"crossref","unstructured":"Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977;35: 1-39.","DOI":"10.1038\/bjc.1977.1"},{"key":"2019111806360633500_REF23","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life-tables. J Royal Stat Soc. 1972;34: 187-220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2019111806360633500_REF24","doi-asserted-by":"crossref","unstructured":"Zipursky A, Christensen H, De Harven E. Ultrastructural studies of megakaryoblastic leukemias of Down syndrome. Leuk Lymphoma. 1995;18: 341-347.","DOI":"10.3109\/10428199509059628"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Zipursky A, Brown EJ, Christensen H, et al. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations. Clin Lab Med. 1999;19: 157-167.","DOI":"10.1016\/S0272-2712(18)30133-1"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Yumura-Yagi K, Hara J, Kurahashi H, et al. Mixed phenotype of blasts in acute megakaryocytic leukemia and transient abnormal myelopoiesis in Down syndrome. Br J Haematol. 1992;81: 520-525.","DOI":"10.1111\/j.1365-2141.1992.tb02985.x"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Worth L, Zipursky A, Christensen H, et al. Transient leukemia with extreme basophilia in a phenotypically normal infant with blast cells containing a pseudodiploid clone, 46, XY I(21(q10)). J Pediatr Hematol Oncol. 1999;21: 63-66.","DOI":"10.1097\/00043426-199901000-00014"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Suda T, Suda J, Miura Y, et al. Clonal analysis of basophil differentiation in bone marrow cultures from a Down syndrome patient with megakaryoblastic leukemia. Blood. 1985;66: 1278-1283.","DOI":"10.1182\/blood.V66.6.1278.1278"},{"key":"2019111806360633500_REF29","doi-asserted-by":"crossref","unstructured":"Ito E, Kasai M, Hayashi Y, et al. Expression of erythroid specific genes in acute megakaryoblastic leukemia and transient myeloproliferative disorder in Down syndrome. Br J Haematol. 1995;90: 607-614.","DOI":"10.1111\/j.1365-2141.1995.tb05591.x"},{"key":"2019111806360633500_REF30","doi-asserted-by":"crossref","unstructured":"Kurahashi H, Hara J, Yumura-Yagi K, et al. Monoclonal nature of transient abnormal myelopoiesis in Down syndrome. Blood. 1991;77: 1161-1163.","DOI":"10.1182\/blood.V77.6.1161.1161"},{"key":"2019111806360633500_REF31","unstructured":"Miyashita T, Asada M, Fujimoto J, et al. Clonal analysis of transient myeloproliferative disorder in Down syndrome. Leukemia. 1991;5: 56-59."},{"key":"2019111806360633500_REF32","doi-asserted-by":"crossref","unstructured":"Baschat AA, Wagner T, Malisius R, et al. Prenatal diagnosis of a transient myeloproliferative disorder in trisomy 21. Prenat Diagn. 1998;18: 731-736.","DOI":"10.1002\/(SICI)1097-0223(199807)18:7<731::AID-PD322>3.0.CO;2-A"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"de Tar MW, Dittman W, Gilbert J. Transient myeloproliferative disease of the newborn: case report with placental, cytogenetic and flow cytometric findings. Hum Pathol. 2000;31: 396-398.","DOI":"10.1016\/S0046-8177(00)80257-9"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Donnenfeld AE, Scott SC, Henselder-Kimmel M, et al. Prenatally diagnosed non-immune hydrops caused by congenital transient leukemia. Prenat Diagn. 1994;14: 721-724.","DOI":"10.1002\/pd.1970140812"},{"key":"2019111806360633500_","unstructured":"Hendricks S, Sorensen T T, Baker E. Trisomy 21, fetal hydrops and anemia: prenatal diagnosis of transient myeloproliferative disorder. Obstet Gynecol. 1993;82: 703-705."},{"key":"2019111806360633500_REF36","doi-asserted-by":"crossref","unstructured":"Yagihashi N, Watanabe K, Yagihashi S. Transient abnormal myelopoiesis accompanied by hepatic fibrosis in two infants with Down syndrome. J Clin Pathol. 1995;48: 973-975.","DOI":"10.1136\/jcp.48.10.973"},{"key":"2019111806360633500_REF37","doi-asserted-by":"crossref","unstructured":"Ravindranath Y, Abella E, Krischer J, et al. Acute myeloid leukemia (AML) in Down syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology AML study 8498. Blood. 1992;80: 2210-2214.","DOI":"10.1182\/blood.V80.9.2210.2210"},{"key":"2019111806360633500_","unstructured":"Lange B, Kobrinsky N, Barnard D, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group studies 2861 and 2891. Blood. 1998;91: 608-615."},{"key":"2019111806360633500_REF39","doi-asserted-by":"crossref","unstructured":"Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome. Leukemia. 2000;14: 786-791.","DOI":"10.1038\/sj.leu.2401754"},{"key":"2019111806360633500_REF40","unstructured":"Doyle JJ, Zipursky A. Down syndrome children with neonatal transient leukemia. Survival and risk of subsequent myelodysplasia and leukemia [abstract]. Blood. 1994;84: 316a."},{"key":"2019111806360633500_REF41","unstructured":"Kwong YL, Cheng G, Tang TS, et al. Transient myeloproliferative disorder in a Down's neonate with rearranged T-cell receptor beta gene and evidence of in vivo maturation demonstrated by dual-colour flow cytometric DNA ploidy analysis. Leukemia. 1993;7: 1667-1671."},{"key":"2019111806360633500_REF42","doi-asserted-by":"crossref","unstructured":"Tsuboi K, Yazaki M, Miwa H, et al. Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndrome. Int J Hematol. 2002;76: 69-73.","DOI":"10.1007\/BF02982721"},{"key":"2019111806360633500_REF43","doi-asserted-by":"crossref","unstructured":"Cavani S, Perfumo C, Argusti A, et al. Cytogenetic and molecular study of 32 Down syndrome families: potential leukaemia predisposing role of the most proximal segment of chromosome 21q. Br J Haematol. 1998;103: 213-216.","DOI":"10.1046\/j.1365-2141.1998.00924.x"},{"key":"2019111806360633500_REF44","doi-asserted-by":"crossref","unstructured":"Abe K, Kajii T, Niikawa N. Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative disorder. Hum Genet. 1989;82: 213-216.","DOI":"10.1007\/BF00273988"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Lorber BJ, Freeman SB, Hassold T, et al. Characterization and molecular analysis of nondisjunction in 18 cases of trisomy 21 and leukemia. Genes Chromosomes Cancer. 1992;4: 222-227.","DOI":"10.1002\/gcc.2870040306"},{"key":"2019111806360633500_REF46","unstructured":"Shea J, Williams B, Zipursky A, et al. Cytogenetic and molecular studies of Down syndrome individuals with leukemia. Am J Hum Genet. 1995;56: 915-925."},{"key":"2019111806360633500_REF47","doi-asserted-by":"crossref","unstructured":"Ho C, Otterud B, Legare R, et al. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood. 1996;87: 5218-5224.","DOI":"10.1182\/blood.V87.12.5218.bloodjournal87125218"},{"key":"2019111806360633500_REF48","doi-asserted-by":"crossref","unstructured":"Okuda T, van Deursen J, Hiebert S, et al. AML 1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84: 321-330.","DOI":"10.1016\/S0092-8674(00)80986-1"},{"key":"2019111806360633500_REF49","doi-asserted-by":"crossref","unstructured":"Breton-Gorius J, Bizet M, Reyes F, et al. Myelofibrosis and acute megakaryoblastic leukemia in a child: topographic relationship between fibroblasts and megakaryocytes with alpha granule defect. Leuk Res. 1982;6: 97-110.","DOI":"10.1016\/0145-2126(82)90048-0"},{"key":"2019111806360633500_REF50","doi-asserted-by":"crossref","unstructured":"Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor beta in acute megakaryoblastic leukemia and its possible implication in myelofibrosis. Blood. 1990;75: 1540-1548.","DOI":"10.1182\/blood.V75.7.1540.1540"},{"key":"2019111806360633500_REF51","doi-asserted-by":"crossref","unstructured":"Martin D, Zon L, Mutter G et al. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature. 1990;344: 444-447.","DOI":"10.1038\/344444a0"},{"key":"2019111806360633500_REF52","doi-asserted-by":"crossref","unstructured":"Romeo P, Prandini M, Joulin V, et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature. 1990;344: 447-449.","DOI":"10.1038\/344447a0"},{"key":"2019111806360633500_REF53","doi-asserted-by":"crossref","unstructured":"Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32: 148-152.","DOI":"10.1038\/ng955"},{"key":"2019111806360633500_","doi-asserted-by":"crossref","unstructured":"Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101: 4298-4300.","DOI":"10.1182\/blood-2002-12-3904"},{"key":"2019111806360633500_REF55","doi-asserted-by":"crossref","unstructured":"Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101: 4301-4304.","DOI":"10.1182\/blood-2003-01-0013"},{"key":"2019111806360633500_REF56","doi-asserted-by":"crossref","unstructured":"Taub J, Mundschau G, Ge Y, et al. Prenatal origin of GATA 1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood. 2004;104: 1588-1589.","DOI":"10.1182\/blood-2004-04-1563"},{"key":"2019111806360633500_REF57","unstructured":"Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94: 1393-1400."},{"key":"2019111806360633500_REF58","unstructured":"Taub JW, Huang X, Ge Y, et al. Cystathione-beta-synthase cDNA transfection alters the sensitivity of metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Cancer Res. 2000;60: 6421-6426."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/12\/4606\/1278485\/zh801206004606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/12\/4606\/1278485\/zh801206004606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T19:34:11Z","timestamp":1627068851000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/12\/4606\/129256\/A-prospective-study-of-the-natural-history-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,15]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2448","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,15]]}}}